As Chief Medical Officer and Executive Vice President, Corporate Business Development, Lanman lectured nationally on preventive cardiology and lipidology and coordinated studies using the VAP test's unique lipoprotein (a) (Lp(a)) cholesterol measurement and other lipoprotein biomarkers in published clinical studies including the Framingham Heart Study, Hopkins Sibling Heart Study and the HDL Atherosclerosis Intervention Trial.